Abstract 1670
Background
International recommendations for cancer control support the organization of breast cancer care with a multidisciplinary approach in Breast Units (BU). The BU of the Catalan Institute of Oncology (ICO) is a functional unit for breast cancer with oncologists, gynecologists, surgeons and cancer nurses specialized in for diagnosis, treatment and monitoring breast cancer patients. Pathologists and radiologists are also working with the BU. Several international guidelines include nurse as essential part of BU and defined their model of care, management and functions.
The objective is to describe care nurse model and activity of the Breast Unit in a cancer center.
Methods
Retrospective cross-sectional study. Population cancer patients attended at the BU of the ICO during 2016 to 2017 were included. Variables collected were socio-demographic, clinical - pathology and treatment and nursing interventions for patients. Data was extracted from the clinical record. Data analysis was descriptive using the statistical package SPSS v15.
Results
Total of 382 patients. Nursing interventions in patients with early stage breast cancer were: 321 (98.85%) visits before the start of treatments; 322 (99.1%) visits during treatments; 230 (70.8%) visits after finishing treatments; 319 (98.2%) coordination activities for the continuity of care and 136 (14.8%) consultations and derivations to professionals of other services.
Nursing interventions in patients with advanced stage breast cancer: 32 (56.1%) visits before the start of treatments; 33 (57.9%) visits during treatments; 17 (29.8%) coordination activities for the continuity of care; and 12 (21.8%) consultations and derivations to professionals of other services.
Conclusions
According to this multidisciplinary model of care, patients with breast cancer in the early stages have a high level of clinical contacts with the nurse along the cancer care process. However, there is a high percentage of patients with advanced disease that could not benefit from an early and continued access to nurse.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Generalitat of Catalonia, Department of Health.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5105 - Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: association with toxicity and treatment outcome
Presenter: Aude DESNOYER
Session: Poster Display session 3
Resources:
Abstract
1877 - Advanced clear-cell renal cell carcinoma (accRCC): association of microRNAs (miRNAs) with molecular subtypes, mRNA targets and outcome.
Presenter: Annelies Verbiest
Session: Poster Display session 3
Resources:
Abstract
5543 - Prior tyrosine kinase inhibitors (TKI) and antibiotics (ATB) use are associated with distinct gut microbiota ‘guilds’ in renal cell carcinoma (RCC) patients
Presenter: Valerio Iebba
Session: Poster Display session 3
Resources:
Abstract
2689 - mTOR mutations are not associated with shorter PFS and OS in patients treated with mTOR inhibitors
Presenter: Cristina Suarez Rodriguez
Session: Poster Display session 3
Resources:
Abstract
3069 - Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in Advanced Renal Cell Carcinoma (RCC)
Presenter: Aly-Khan Lalani
Session: Poster Display session 3
Resources:
Abstract
5089 - Finding the Right Biomarker for Renal Cell Carcinoma (RCC): Nivolumab treatment induces the expression of specific peripheral lymphocyte microRNAs in patients with durable and complete response.
Presenter: Lorena Incorvaia
Session: Poster Display session 3
Resources:
Abstract
2594 - Algorithms derived from quantitative pathology can be a gatekeeper in patient selection for clinical trials in localised clear cell renal cell carcinoma (ccRCC)
Presenter: In Hwa Um
Session: Poster Display session 3
Resources:
Abstract
2566 - High baseline blood volume is an independent favorable prognostic factor for overall and progression-free survival in patients with metastatic renal cell carcinoma
Presenter: Aska Drljevic-nielsen
Session: Poster Display session 3
Resources:
Abstract
2675 - Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC)
Presenter: Daniel George
Session: Poster Display session 3
Resources:
Abstract
1541 - TERT gene fusions characterize a subset of metastatic Leydig cell tumors
Presenter: Bozo Kruslin
Session: Poster Display session 3
Resources:
Abstract